Shares of Intellia Therapeutics (NTLA) are on the rise on Monday after the company and partner Regeneron (REGN) announced positive results from a Phase 1 study of a gene-editing treatment for transthyretin amyloidosis. Over the weekend,… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3327300/-Intellia-Therapeutics-shares-jump-on-milestone-for-genome-editing)
previous post